Stephen E. Kimmel, MD, MSCE
Dr. Kimmel performs clinical studies of medications and randomized trials of interventions to improve medical treatments. His work includes large-scale population studies, such as a more-than-8,500 person study examining the effects of non-steroidal anti-inflammatory drugs and COX-2 inhibitors on myocardial infarction; and a multi-center prospective cohort of genetic and adherence determinants of warfarin response. He was a principal investigator on a multicenter clinical trial, funded by the Pennsylvania Department of Health and industry support, that was designed to improve adherence and thus blood pressure control with antihypertensive medications. He has served as principal investigator on an R01-funded multicenter trial of lottery incentives and reminder systems for warfarin treated patients. He was also the principal investigator for the Clinical Trial Coordinating Center of a large, National Heart, Lung and Blood Institute-sponsored, multicenter clinical trial of pharmacogenetic-based dosing of warfarin, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Current work includes patient-centered outcomes research in heart failure, novel methods for prediction modeling, and innovative methods of improving adherence.
Cardiovascular disease, adherence
Cardiovascular epidemiology, clinical trials, pharmacogenetics, pharmacoepidemiology